Mito Target is a resource for ALS information and research

The Project

Mitochondrial dysfunction is a major hallmark of various neurodegenerative disorders including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and Amyotrophic Lateral Sclerosis (ALS). The links between mitochondrial dysfunction and the onset and progress of some of these diseases, however, still needs to be explained in more detail. In diseases where this link is already established, the question remains whether drugs developed with regard to specific targets or mechanisms involved in mitochondrial dysfunction can affect the diseases in question. Read more about the project

Latest News

Disappointing results of olesoxime clinical trial announced

13 December 2011

13 December 2011 Results from a recent clinical trial into motor neurone disease (MND), involving people with MND in England, have been announced and show the trial drug to be ineffective a

Trophos announces results of phase 3 study of olesoxime in ALS

13 December 2011

MARSEILLE, FRANCE – December 13 2011. Trophos SA announces today the results from the phase 3 study of Trophos’ lead compound, olesoxime, in 512 patients with ALS.